BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 37] [Cited by in F6Publishing: 135] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 de Oliveria Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1:33-37. [PMID: 20300384 DOI: 10.4103/0974-777x.52979] [Cited by in Crossref: 93] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
2 Bodlaj G, Hubmann R, Saleh K, Stojakovic T, Biesenbach G, Berg J. Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response. World J Gastroenterol 2010; 16(19): 2407-2410 [PMID: 20480527 DOI: 10.3748/wjg.v16.i19.2407] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM, Wang E, Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med 2009;7:85. [PMID: 19821982 DOI: 10.1186/1479-5876-7-85] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
4 Yu X, Sainz B Jr, Petukhov PA, Uprichard SL. Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay. Antimicrob Agents Chemother 2012;56:6109-20. [PMID: 22948883 DOI: 10.1128/AAC.01413-12] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Jan CF, Chen CJ, Chen HH. Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. J Gastroenterol Hepatol. 2005;20:521-526. [PMID: 15836699 DOI: 10.1111/j.1440-1746.2005.03602.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
6 Izzo F, Montella M, Orlando AP, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, Curley SA, Orlando R, Scordino F, Korba BE. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 2007;22:86-91. [DOI: 10.1111/j.1440-1746.2006.04463.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
7 Sewell JL, Stick KM, Monto A. Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol 2009;21:225-9. [PMID: 19212213 DOI: 10.1097/MEG.0b013e32831101b7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
8 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 15.3] [Reference Citation Analysis]
9 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, Butt AA. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59-64. [PMID: 19566787 DOI: 10.1111/j.1365-2893.2009.01151.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
11 Jiang JJ, Shiels MS, O'Brien TR. Death certificates compared to SEER-Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection. J Viral Hepat 2021;28:934-41. [PMID: 33720473 DOI: 10.1111/jvh.13498] [Reference Citation Analysis]
12 Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006;101:2737-43. [PMID: 17227521 DOI: 10.1111/j.1572-0241.2006.00831.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
13 Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, Moriwaki H, Kojima S. Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 2011;10:4. [PMID: 21214951 DOI: 10.1186/1476-4598-10-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
14 Ahmad W, Ijaz B, Javed FT, Kausar H, Sarwar MT, Gull S, Asad S, Shahid I, Hassan S. HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. Virol J 2011;8:293. [PMID: 21663629 DOI: 10.1186/1743-422X-8-293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
15 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 Wang Y, Ganger DR, Levitsky J, Sternick LA, McCarthy RJ, Chen ZE, Fasanati CW, Bolster B, Shah S, Zuehlsdorff S. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol. 2011;196:553-561. [PMID: 21343496 DOI: 10.2214/ajr.10.4580] [Cited by in Crossref: 161] [Cited by in F6Publishing: 94] [Article Influence: 14.6] [Reference Citation Analysis]
17 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
18 Inokawa Y, Inaoka K, Sonohara F, Hayashi M, Kanda M, Nomoto S. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 2016;12:3662-8. [PMID: 27900050 DOI: 10.3892/ol.2016.5141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
19 Liu X, Zhu L, Ma J, Qiao X, Zhu D, Liu L, Leng X. Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide. Drug Deliv Transl Res 2017;7:147-55. [PMID: 27896668 DOI: 10.1007/s13346-016-0348-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Mustafa GM, Larry D, Petersen JR, Elferink CJ. Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol 2015; 7(10): 1312-1324 [PMID: 26052377 DOI: 10.4254/wjh.v7.i10.1312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
21 Fujita N, Takei Y. Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J Gastroenterol 2007;42:923-6. [PMID: 18008038 DOI: 10.1007/s00535-007-2110-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
22 Yoshida T, Ogata H, Kamio M, Joo A, Shiraishi H, Tokunaga Y, Sata M, Nagai H, Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med. 2004;199:1701-1707. [PMID: 15197228 DOI: 10.1084/jem.20031675] [Cited by in Crossref: 116] [Cited by in F6Publishing: 116] [Article Influence: 6.4] [Reference Citation Analysis]
23 Tholey DM, Hornung B, Enestvedt CK, Chen Y, Naugler WS, Farsad K, Nabavizadeh N, Schlansky B, Ahn J, Jou JH. Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol 2017;4:e000157. [PMID: 28944072 DOI: 10.1136/bmjgast-2017-000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Tanaka H, Fujita N, Sugimoto R, Urawa N, Horiike S, Kobayashi Y, Iwasa M, Ma N, Kawanishi S, Watanabe S, Kaito M, Takei Y. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008;98:580-6. [PMID: 18231107 DOI: 10.1038/sj.bjc.6604204] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 5.9] [Reference Citation Analysis]
25 Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015;60:420-6. [PMID: 25381201 DOI: 10.1007/s10620-014-3364-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
26 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063-016-1454-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
27 Mendes LS, Nita ME, Ono-Nita SK, Mello ES, Silva LCD, Alves VA, Carrilho FJ. Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol 2008; 14(16): 2522-2528 [PMID: 18442199 DOI: 10.3748/wjg.14.2522] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wong LL, Tsai N, Limm W, Wong L. Liver transplant for hepatocellular cancer: a treatment for the select few. Clin Transplant 2004;18:205-10. [PMID: 15016137 DOI: 10.1046/j.1399-0012.2003.00157.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
29 Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M, Shibata H, Sato S, Miyaaki H, Nakao K. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Intern Med 2020;59:901-7. [PMID: 32238660 DOI: 10.2169/internalmedicine.3382-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sieja KS, Everson GT. De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci 2006;51:600-2. [PMID: 16614973 DOI: 10.1007/s10620-006-3176-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
31 Aituov B, Duisembekova A, Bulenova A, Alibek K. Pathogen-driven gastrointestinal cancers: Time for a change in treatment paradigm? Infect Agent Cancer. 2012;7:18. [PMID: 22873119 DOI: 10.1186/1750-9378-7-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
32 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63 Suppl 2:ii18-ii24. [PMID: 15479865 DOI: 10.1136/ard.2004.028209] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.6] [Reference Citation Analysis]
34 Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:268-76. [PMID: 23419289 DOI: 10.1038/nrgastro.2013.17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
35 Riaz A, Lewandowski RJ, Salem R. Locoregional Therapies for Primary and Secondary Hepatic Malignancies. In: Bentrem D, Benson AB, editors. Gastrointestinal Malignancies. Cham: Springer International Publishing; 2016. pp. 233-56. [DOI: 10.1007/978-3-319-34244-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Ijaz B, Ahmad W, Javed FT, Gull S, Sarwar MT, Kausar H, Asad S, Jahan S, Khaliq S, Shahid I. Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J. 2011;8:361. [PMID: 21777434 DOI: 10.1186/1743-422x-8-361] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
37 Giles M, Hellard M, Sasadeusz J. Hepatitis C and pregnancy: an update. Aust N Z J Obstet Gynaecol 2003;43:290-3. [PMID: 14714713 DOI: 10.1046/j.0004-8666.2003.00083.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
38 Rocha M, Avenaud P, Ménard A, Le Bail B, Balabaud C, Bioulac-Sage P, de Magalhães Queiroz DM, Mégraud F. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 2005;54:396-401. [PMID: 15710989 DOI: 10.1136/gut.2004.042168] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 6.2] [Reference Citation Analysis]
39 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB 3rd, Nemcek AA Jr, Omary R, Salem R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010;303:1062-9. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 145] [Cited by in F6Publishing: 134] [Article Influence: 12.1] [Reference Citation Analysis]
40 Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 2011;85:7989-8001. [PMID: 21680513 DOI: 10.1128/JVI.00280-11] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
41 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
42 Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Omary RA, Benson AB 3rd, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010;255:955-65. [PMID: 20501733 DOI: 10.1148/radiol.10091473] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
43 Krishnamurthy P, Hazratjee N, Opris D, Agrawal S, Markert R. Is exposure to Agent Orange a risk factor for hepatocellular cancer?-A single-center retrospective study in the U.S. veteran population. J Gastrointest Oncol 2016;7:426-32. [PMID: 27284476 DOI: 10.21037/jgo.2016.01.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AEE, Mestiri H, Benazzouz M, Khalfallah T, Afifi R, Elkihal L, Berkane S, Marchio A, Debzi N, Dejean A, Pineau P, Triki H, Benjelloun S. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol 2011; 3(1): 24-30 [PMID: 21307984 DOI: 10.4254/wjh.v3.i1.24] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
45 Wu Y, Yao N, Feng Y, Tian Z, Yang Y, Zhao Y. Identification and characterization of sexual dimorphism‑linked gene expression profile in hepatocellular carcinoma. Oncol Rep 2019;42:937-52. [PMID: 31322260 DOI: 10.3892/or.2019.7217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
46 Chen Y, Shen C, Guha D, Ding M, Kulich S, Ashimkhanova A, Rinaldo C, Seaberg E, Margolick JB, Stosor V, Martínez-Maza O, Gupta P. Identification of the transcripts associated with spontaneous HCV clearance in individuals co-infected with HIV and HCV. BMC Infect Dis 2016;16:693. [PMID: 27875997 DOI: 10.1186/s12879-016-2044-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
47 Higgs MR, Lerat H, Pawlotsky JM. Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res. 2010;70:4901-4911. [PMID: 20530689 DOI: 10.1158/0008-5472.CAN-09-4554] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
48 Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007;188:758-764. [PMID: 17312065 DOI: 10.2214/ajr.06.0322] [Cited by in Crossref: 222] [Cited by in F6Publishing: 76] [Article Influence: 14.8] [Reference Citation Analysis]
49 Mishra S, Lavelle BJ, Desrosiers J, Ardito MT, Terry F, Martin WD, De Groot AS, Gregory SH. Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice. PLoS One. 2014;9:e104606. [PMID: 25111185 DOI: 10.1371/journal.pone.0104606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
50 Heidecke S, Stippel DL, Hoelscher AH, Wedemeyer I, Dienes HP, Drebber U. Simultaneous occurrence of a hepatocellular carcinoma and a hepatic non-Hodgkin’s lymphoma infiltration. World J Hepatol 2010; 2(6): 246-250 [PMID: 21161005 DOI: 10.4254/wjh.v2.i6.246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007;50:361-368. [PMID: 17728547 DOI: 10.1159/000107707] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
52 Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013;7:87-102. [PMID: 23761989 DOI: 10.4137/CMO.S7633] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
53 Baniasadi H, Gowda GA, Gu H, Zeng A, Zhuang S, Skill N, Maluccio M, Raftery D. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis 2013;34:2910-7. [PMID: 23856972 DOI: 10.1002/elps.201300029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
54 Hoffmann K, Xiao Z, Franz C, Mohr E, Serba S, Büchler MW, Schemmer P. Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int. 2011;11:40. [PMID: 22088142 DOI: 10.1186/1475-2867-11-40] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
55 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
56 Chen JY, Li F. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J Gastroenterol 2006; 12(48): 7774-7778 [PMID: 17203519 DOI: 10.3748/wjg.v12.i48.7774] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
57 Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016;17:331. [PMID: 27439433 DOI: 10.1186/s13063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence. 2012;3:610-620. [PMID: 23076334 DOI: 10.4161/viru.21823] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
59 Shields A, Reddy KR. Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 2005;8:457-66. [PMID: 16313863 DOI: 10.1007/s11938-005-0032-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
61 El Hadad S, Al-Hamdan H, Linjawi S. Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia. PLoS One 2017;12:e0178225. [PMID: 28552946 DOI: 10.1371/journal.pone.0178225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
62 Titan AL, Devereaux K, Louie JD, Poultsides GA. Clinical Trigonometry: Right Hepatic Trisegmentectomy After Radiation Trisegmentectomy for Hepatocellular Carcinoma. Dig Dis Sci 2018;63:1419-23. [PMID: 29119415 DOI: 10.1007/s10620-017-4797-2] [Reference Citation Analysis]
63 Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-92. [PMID: 20425078 DOI: 10.1007/s11912-010-0094-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
64 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 366] [Article Influence: 32.5] [Reference Citation Analysis]
65 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
66 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 14.4] [Reference Citation Analysis]
67 Jou JH, Chen PH, Jazwinski A, Bouneva I, Smith AD, Muir AJ. Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center. Dig Dis Sci. 2010;55:3591-3596. [PMID: 20683659 DOI: 10.1007/s10620-010-1366-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
68 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
69 Liu L, Dong X, Zhu D, Song L, Zhang H, Leng XG. TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells. Int J Nanomedicine 2014;9:2879-89. [PMID: 24959076 DOI: 10.2147/IJN.S61392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
70 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD;  HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 367] [Article Influence: 28.6] [Reference Citation Analysis]
71 Sun JH, Zhang YL, Nie CH, Chen LM, He JD, Wang WL, Zheng SS. Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study. Oncol Lett 2012;3:975-7. [PMID: 22783375 DOI: 10.3892/ol.2012.618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
72 Molvar C, Lewandowski R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts. Semin Intervent Radiol 2015;32:388-97. [PMID: 26622103 DOI: 10.1055/s-0035-1564704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
73 Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, Nguyen KK, Nguyen MH. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int. 2010;4:523-529. [PMID: 20827411 DOI: 10.1007/s12072-010-9181-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
74 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
75 Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA. Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009;87:143-52. [PMID: 19136905 DOI: 10.1097/TP.0b013e318191c68d] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
76 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 10.6] [Reference Citation Analysis]
77 Mair RD, Valenzuela A, Ha NB, Ayoub WS, Daugherty T, Lutchman GA, Garcia G, Ahmed A, Nguyen MH. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies. Clin Gastroenterol Hepatol 2012;10:1412-7. [PMID: 22902757 DOI: 10.1016/j.cgh.2012.08.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
78 de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol 2015; 21(39): 11185-11198 [PMID: 26494973 DOI: 10.3748/wjg.v21.i39.11185] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
79 Zendejas-ruiz I, Hemming AW, Chen C, Schwartz JJ, Sorensen JB, Kim RD. Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients with Hepatitis C. J Gastrointest Canc 2012;43:229-35. [DOI: 10.1007/s12029-010-9230-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
80 Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, Nakao K. Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med 2012;4:972-6. [PMID: 23226758 DOI: 10.3892/etm.2012.709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
81 Ahmad W, Shabbiri K, Ijaz B, Asad S, Sarwar MT, Gull S, Kausar H, Fouzia K, Shahid I, Hassan S. Claudin-1 required for HCV virus entry has high potential for phosphorylation and O-glycosylation. Virol J 2011;8:229. [PMID: 21569618 DOI: 10.1186/1743-422X-8-229] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
82 Akiel M, Rajasekaran D, Gredler R, Siddiq A, Srivastava J, Robertson C, Jariwala NH, Fisher PB, Sarkar D. Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:9-19. [PMID: 27508172 DOI: 10.2147/JHC.S44460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H, Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563-71. [PMID: 16998365 DOI: 10.1097/01.sla.0000237648.90600.e9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
84 Xiao J, Zhao Y, Varghese RS, Zhou B, Di Poto C, Zhang L, Tadesse MG, Ziada DH, Shetty K, Ressom HW. Evaluation of metabolite biomarkers for hepatocellular carcinoma through stratified analysis by gender, race, and alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev 2014;23:64-72. [PMID: 24186894 DOI: 10.1158/1055-9965.EPI-13-0327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
85 Taura N, Ichikawa T, Miyaaki H, Ozawa E, Tsutsumi T, Tsuruta S, Kato Y, Goto T, Kinoshita N, Fukushima M, Kato H, Ohata K, Ohba K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit 2013;19:742-50. [PMID: 24008520 DOI: 10.12659/MSM.889361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
86 El-Baz FK, Salama A, Ali SI, Elgohary R. Haematococcus pluvialis Carotenoids Enrich Fractions Ameliorate Liver Fibrosis Induced by Thioacetamide in Rats: Modulation of Metalloproteinase and Its Inhibitor. Biomed Res Int 2021;2021:6631415. [PMID: 33628797 DOI: 10.1155/2021/6631415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Chang ML, Lai PC, Yeh CT. Sustained eradication of hepatitis C virus by low-dose long-term interferon therapy in a renal transplant recipient with dual infection with hepatitis B and C viruses: a case report. J Med Case Rep 2011;5:246. [PMID: 21714861 DOI: 10.1186/1752-1947-5-246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Idrees M, Rafique S, Rehman IU, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009; 15(40): 5080-5085 [PMID: 19860002 DOI: 10.3748/wjg.15.5080] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
89 Goldsmith J, Hauser P. Psychiatric Issues in Patients with Hepatitis C. Psychiatric Annals 2003;33:357-60. [DOI: 10.3928/0048-5713-20030601-04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
90 Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15:85-94. [PMID: 19098997 DOI: 10.2119/molmed.2008.00110] [Cited by in Crossref: 159] [Cited by in F6Publishing: 164] [Article Influence: 11.4] [Reference Citation Analysis]
91 Sun S, Li Y, Han S, Jia H, Li X, Li X. A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma. BMC Med Genomics 2019;12:147. [PMID: 31660973 DOI: 10.1186/s12920-019-0580-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
92 Khalid J, Umar M, Ur-Rehman T, Ali M, Khan GM. Tumor aggression among hepatitis-C related hepatocellular carcinoma patients: an observational study regarding the impact of anti-HCV therapy. Infect Agent Cancer 2020;15:35. [PMID: 32508980 DOI: 10.1186/s13027-020-00300-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Sun JH, Zhang YL, Nie CH, Yu XB, Xie HY, Zhou L, Zheng SS. Considerations for two inoculation methods of rabbit hepatic tumors: Pathology and image features. Exp Ther Med 2012;3:386-90. [PMID: 22969900 DOI: 10.3892/etm.2011.435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
94 Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, Alexander GJ. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 2005;79:7852-9. [PMID: 15919939 DOI: 10.1128/JVI.79.12.7852-7859.2005] [Cited by in Crossref: 211] [Cited by in F6Publishing: 90] [Article Influence: 12.4] [Reference Citation Analysis]
95 Hanczko R, Fernandez DR, Doherty E, Qian Y, Vas G, Niland B, Telarico T, Garba A, Banerjee S, Middleton FA, Barrett D, Barcza M, Banki K, Landas SK, Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest 2009;119:1546-57. [PMID: 19436114 DOI: 10.1172/JCI35722] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
96 Kousik V, Promila P, Verma R, Gupta A. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases. Indian J Gastroenterol 2016;35:179-85. [PMID: 27185180 DOI: 10.1007/s12664-016-0657-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
97 Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L. Peroxisome proliferator-activated receptors in HCV-related infection. PPAR Res. 2009;2009:357204. [PMID: 19343188 DOI: 10.1155/2009/357204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
98 Ahmad W, Ijaz B, Hassan S. Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray. J Transl Med 2012;10:41. [PMID: 22397681 DOI: 10.1186/1479-5876-10-41] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
99 Estevez J, Chen VL, Podlaha O, Li B, Le A, Vutien P, Chang ET, Rosenberg-Hasson Y, Jiang Z, Pflanz S, Ge D, Gaggar A, Nguyen MH. Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma. Sci Rep 2017;7:11867. [PMID: 28928388 DOI: 10.1038/s41598-017-11975-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
100 Scoparo CT, Valdameri G, Worfel PR, Guterres FALB, Martinez GR, Winnischofer SMB, Di Pietro A, Rocha MEM. Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity. Mol Cell Biochem 2015;409:123-33. [DOI: 10.1007/s11010-015-2518-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
101 Yalamanchili K, Saadeh S, Lepe R, Davis GL. The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) 2005;18:3-6. [PMID: 16200141 DOI: 10.1080/08998280.2005.11928024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
102 Nasr MA, Salah RA, Abd Elkodous M, Elshenawy SE, El-Badri N. Dysregulated MicroRNA Fingerprints and Methylation Patterns in Hepatocellular Carcinoma, Cancer Stem Cells, and Mesenchymal Stem Cells. Front Cell Dev Biol 2019;7:229. [PMID: 31681762 DOI: 10.3389/fcell.2019.00229] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
103 Asghar K, Ashiq MT, Zulfiqar B, Mahroo A, Nasir K, Murad S. Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis. Exp Ther Med. 2015;9:901-904. [PMID: 25667650 DOI: 10.3892/etm.2014.2146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
104 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
105 Majidzadeh-A K, Morovvati A, Soleimani M, Langeroudi AG, Merat S, Jabbari H. Development and Application of an In-house Line Probe Assay for Hepatitis C Virus Genotyping. Hepat Mon 2013;13:e6767. [PMID: 23922557 DOI: 10.5812/hepatmon.6767] [Reference Citation Analysis]
106 Lo Re V 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009;18:807-14. [PMID: 19551699 DOI: 10.1002/pds.1784] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
107 El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4:5-10. [PMID: 21317990 DOI: 10.1177/1756283x10385964] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
108 Jiang T, Tian G, Zhao Q, Kong D, Cheng C, Zhong L, Li L. Diagnostic Accuracy of 2D-Shear Wave Elastography for Liver Fibrosis Severity: A Meta-Analysis. PLoS One 2016;11:e0157219. [PMID: 27300569 DOI: 10.1371/journal.pone.0157219] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
109 De Giorgi V, Buonaguro L, Worschech A, Tornesello ML, Izzo F, Marincola FM, Wang E, Buonaguro FM. Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013;8:e56153. [PMID: 23441164 DOI: 10.1371/journal.pone.0056153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
110 Doyle MA, Cooper C. Successful Hepatitis C Antiviral Therapy Induces Remission of Type 2 Diabetes: A Case Report. Am J Case Rep 2015;16:745-50. [PMID: 26482468 DOI: 10.12659/ajcr.895064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
111 Ogihara M, Wong LL, Machi J. Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: long-term outcomes. HPB (Oxford). 2005;7:214-221. [PMID: 18333193 DOI: 10.1080/13651820510028846] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
112 Zhang X, Ryu SH, Xu Y, Elbaz T, Zekri AR, Abdelaziz AO, Abdel-Hamid M, Thiers V, Elena SF, Fan X, Di Bisceglie AM. The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. J Clin Virol 2011;52:333-8. [PMID: 21925935 DOI: 10.1016/j.jcv.2011.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
113 Reimer P, Vosshenrich R. Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent. Biologics 2010;4:199-212. [PMID: 20714357 DOI: 10.2147/btt.s6479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
114 Wu MS, Wang CH, Tseng FC, Yang HJ, Lo YC, Kuo YP, Tsai DJ, Tsai WT, Yu GY. Interleukin-17F expression is elevated in hepatitis C patients with fibrosis and hepatocellular carcinoma. Infect Agent Cancer 2017;12:42. [PMID: 28770001 DOI: 10.1186/s13027-017-0152-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
115 Wei MT, Le MH, Landis C, Trinh H, Wong G, Le A, Zhang J, Cheung R, Nguyen MH. Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C. J Med Virol 2021. [PMID: 34219250 DOI: 10.1002/jmv.27168] [Reference Citation Analysis]
116 Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15(26): 3210-3216 [PMID: 19598295 DOI: 10.3748/wjg.15.3210] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
117 Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol 2011; 17(7): 914-921 [PMID: 21412500 DOI: 10.3748/wjg.v17.i7.914] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
118 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
119 Zheng K, Cubero FJ, Nevzorova YA. c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) 2017;8:E123. [PMID: 28422055 DOI: 10.3390/genes8040123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
120 Memon K, Kulik L, Lewandowski RJ, Wang E, Ryu RK, Riaz A, Nikolaidis P, Miller FH, Yaghmai V, Baker T, Abecassis M, Benson AB, Mulcahy MF, Omary RA, Salem R. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012;56:1112-1120. [PMID: 22245905 DOI: 10.1016/j.jhep.2011.11.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
121 Self AA, Losikoff PT, Gregory SH. Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. Hum Vaccin Immunother 2013;9:1569-76. [PMID: 23732899 DOI: 10.4161/hv.24726] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
122 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 10.3] [Reference Citation Analysis]
123 Fujita Y, Shibata A, Ogimoto I, Kurozawa Y, Nose T, Yoshimura T, Suzuki H, Iwai N, Sakata R, Ichikawa S. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer. 2006;94:737-739. [PMID: 16465190 DOI: 10.1038/sj.bjc.6602981] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
124 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 538] [Article Influence: 86.6] [Reference Citation Analysis]
125 Mehinovic L, Islamagic E, Husic-Selimovic A, Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. Open Access Maced J Med Sci 2018;6:1668-73. [PMID: 30337985 DOI: 10.3889/oamjms.2018.344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
126 Lee CM, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH, Yen YH. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. BMC Gastroenterol. 2016;16:73. [PMID: 27457659 DOI: 10.1186/s12876-016-0492-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
127 Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138-148. [PMID: 18848939 DOI: 10.1053/j.gastro.2008.09.014.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S, Jahan S, Pervaiz A, Hassan S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011;11:44. [PMID: 21507271 DOI: 10.1186/1471-230X-11-44] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
129 Kin KC, Lin B, Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Levitt BS, da Silveira EB, Nguyen MH. Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study. Dig Dis Sci 2013;58:3342-7. [PMID: 24081641 DOI: 10.1007/s10620-013-2884-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
130 Giménez-barcons M, Wang C, Chen M, Sánchez-tapias J, Sáiz J, Gale M. The Oncogenic Potential of Hepatitis C Virus NS5A Sequence Variants Is Associated with PKR Regulation. Journal of Interferon & Cytokine Research 2005;25:152-64. [DOI: 10.1089/jir.2005.25.152] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
131 Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 2014;14:e18672. [PMID: 25337143 DOI: 10.5812/hepatmon.18672] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
132 Tabassum A, Samdani MN, Dhali TC, Alam R, Ahammad F, Samad A, Karpiński TM. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med (Berl) 2021;99:1293-309. [PMID: 34047812 DOI: 10.1007/s00109-021-02088-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
133 Zou LQ, Chen J, Pan L, Jiang JZ, Xing W. Comparison of magnetic resonance elastography and diffusion-weighted imaging for staging hepatic fibrosis. Chin Med J (Engl). 2015;128:620-625. [PMID: 25698193 DOI: 10.4103/0366-6999.151659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
134 Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J 2005;81:376-82. [PMID: 15937203 DOI: 10.1136/pgmj.2004.025403] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
135 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
136 Kanda T, Yokosuka O, Imazeki F, Arai M, Saisho H. Enhanced Sensitivity of Human Hepatoma Cells to 5-Fluorouracil by Small Interfering RNA Targeting Bcl-2. DNA and Cell Biology 2005;24:805-9. [DOI: 10.1089/dna.2005.24.805] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]